Clear All
765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
S0115 Bortezomib Velcade 3.5 mg Chemotherapy Proteasome Inhibitor 26S No 2003 Jan 1, 2004 Dec 31, 2004 No Longer Used
C9210 Palonosetron Aloxi 25 mcg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2003 Jan 1, 2004 Dec 31, 2004 No Longer Used
C9216 Abarelix Plenaxis 10 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan 1, 2005 No Longer Used
S0165 Abarelix Plenaxis 100 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan 1, 2005 No Longer Used
A9545 Tositumomab Bexxar, Iodine i-131 Tositumomab, therapeutic Per treatment dose Immunotherapy, Radiopharmaceutical Radioimmunotherapy CD20 No 2003 2014 Jan 1, 2006 In Use
NA Dutasteride Avodart 0.5mg Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Yes 2002 In Use
NA Mesna Mesnex 400 mg Ancillary Therapy Chemoprotective Detoxifying Agent Yes 2002 In Use
C9205 Oxaliplatin Eloxatin unspecified Chemotherapy Alkylating Agent Platinum Compound No 2002 Jul 1, 2003 Dec 31, 2005 No Longer Used
S0179 Megesterol Megace 20 mg Hormonal Therapy Progestin Yes 2002 In Use
S0145 Pegintereferon Alfa-2a Pegasys 180 mcg/mL Immunotherapy Cytokine Interferon No 2002 Jul 1, 2005 In Use
J9213 Interferon Alfa-2a Roeferon- A 3 million units Immunotherapy Cytokine Interferon No 2002 Jan 1, 2009 In Use
J2506 Pegfilgratim (ex Biosimilars) Neulasta 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2002 Jan 26, 2022 In Use
J9263 Oxaliplatin Eloxatin 0.5 mg Chemotherapy Alkylating Agent Platinum Compound No 2002 Jan 1, 2004 In Use
J2783 Rasburicase Elitek, Fasturtec 0.5 mg Ancillary Therapy Metabolic Agent Enzyme No 2002 Jan 1, 2004 In Use
J9395 Fulvestrant Faslodex 25 mg Hormonal Therapy Estrogen Receptor Antagonist No 2002 Jan 1, 2004 In Use
C9117 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct 1, 2002 Dec 31, 2002 No Longer Used
C9118 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct 1, 2002 Dec 31, 2002 No Longer Used
J2505 Pegfilgrastim Neulasta:Neulasta Onpro 6 mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2002 Jan 1, 2004 Jan 26, 2022 No Longer Used
S0087 Alemtuzumab Campath 30 mg Immunotherapy Monoclonal Antibody CD52 No 2001 2012 Jan 1, 2002 Dec 31, 2002 No Longer Used
J9342 Thiotepa (not otherwise specified) Thiotepa 1mg Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine No 2001 Jul 9, 2025 In Use
S0146 Peginterferon Alfa-2b Pegintron, Sylatron 20 mcg/mL Immunotherapy Cytokine Interferon No 2001 Jul 1, 2005 Sep 30, 2010 No Longer Used
J3489 Zoledronic acid Zometa (4 mg/5 ml) 1 mg Ancillary Therapy Bisphosphonate No 2001 Jan 1, 2014 In Use
J9010 Alemtuzumab Campath 10 mg Immunotherapy Monoclonal Antibody CD52 No 2001 2012 Jan 1, 2003 Dec 31, 2015 No Longer Used
Q9979 Alemtuzumab Lemtrada 1 mg Immunotherapy Monoclonal Antibody CD52 No 2001 Oct 1, 2015 Dec 31, 2015 No Longer Used
NA Imatinib mesylate Gleevec 400 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2001 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.